Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1976 Sep;10(3):395–398. doi: 10.1128/aac.10.3.395

Pharmacological Study of Cefazolin During Intermittent and Continuous Infusion: a Crossover Investigation in Humans

J P Thys *, B Vanderkelen †, J Klastersky †
PMCID: PMC429759  PMID: 984782

Abstract

Levels of cefazolin were determined in plasma, urine, bile, and cerebrospinal fluid in humans after a bolus intravenous injection and during a controlled, continuous intravenous infusion. All the patients were studied in a steady-state and crossover fashion. In plasma, the mean peak level after bolus injection (1.5 g) studied in 12 patients was 206.5 μg/ml; during continuous infusion (6 g daily), the mean level remained stable at 52.6 μg/ml. With bolus injection and continuous infusion, respectively, 89.7 and 86.3% of the administered dose of cefazolin were excreted in the urine of nine patients over the 6-h period considered. The levels of cefazolin in common bile duct bile were studied in six cholecystectomized patients. In bile collected during the two 3-h periods of the experiment, the mean concentration of the drug in the bile after bolus injection was 66.9 and 22.0 μg/ml, respectively; during continuous infusion, the corresponding biliary levels were 50.7 and 51.3 μg/ml, respectively. In four neurosurgical patients with an intraventricular catheter, neither bolus injection nor continuous infusion resulted in a demonstrable concentration of cefazolin in the cerebrospinal fluid. The continuous intravenous administration of cefazolin might have some advantage over the intravenous bolus intermittent injections. In plasma, the area under the curve is greater with continuous infusion than with bolus injection. In bile, the levels of cefazolin are more sustained with continuous infusion than with bolus injection. This approach to intravenous administration of cefazolin deserves more pharmacological and clinical trials.

Full text

PDF
395

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armengaud M., Auvergnat J. C., Gleises A. Diffusion de la céfazoline dans le liquide céphalo-rachidien (L.C.R.) en fonction du mode d'administration. Données cliniques humaines et expérimentales animales. Nouv Presse Med. 1975 Mar 1;4(9):668–668. [PubMed] [Google Scholar]
  2. Barza M., Brusch J., Bergeron M. G., Weinstein L. Penetration of antibiotics into fibrin loci in vivo. 3. Intermittent vs. continuous infusion and the effect of probenecid. J Infect Dis. 1974 Jan;129(1):73–78. doi: 10.1093/infdis/129.1.73. [DOI] [PubMed] [Google Scholar]
  3. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brogard J. M., Dorner M., Pinget M., Adloff M., Lavillaureix J. The biliary excretion of cefazolin. J Infect Dis. 1975 Jun;131(6):625–633. doi: 10.1093/infdis/131.6.625. [DOI] [PubMed] [Google Scholar]
  5. Cahn M. M., Levy E. J., Actor P., Pauls J. F. Comparative serum levels and urinary recovery of cefazolin, cephaloridine, and cephalothin in man. J Clin Pharmacol. 1974 Jan;14(1):61–66. doi: 10.1002/j.1552-4604.1974.tb02289.x. [DOI] [PubMed] [Google Scholar]
  6. EAGLE H., FLEISCHMAN R., LEVY M. "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med. 1953 Mar 19;248(12):481–488. doi: 10.1056/NEJM195303192481201. [DOI] [PubMed] [Google Scholar]
  7. Ehrlich H. P., Licko V., Hunt T. K. Kinetics of cephaloridine in experimental wounds. Am J Med Sci. 1973 Jan;265(1):33–44. doi: 10.1097/00000441-197301000-00003. [DOI] [PubMed] [Google Scholar]
  8. Hodges G. R., Saslaw S. Experiences with cefazolin: a new cephalosporin antibiotic. Am J Med Sci. 1973 Jan;265(1):23–32. doi: 10.1097/00000441-197301000-00002. [DOI] [PubMed] [Google Scholar]
  9. Lorber B., Santoro J., Swenson R. M. Letter: Listeria meningitis during cefazolin therapy. Ann Intern Med. 1975 Feb;82(2):226–226. doi: 10.7326/0003-4819-82-2-226_1. [DOI] [PubMed] [Google Scholar]
  10. PLORDE J. J., GARCIA M., PETERSDORF R. G. STUDIES ON THE PATHOGENESIS OF MENINGITIS. IV. PENICILLIN LEVELS IN THE CEREBROSPINAL FLUID IN EXPERIMENTAL MENINGITIS. J Lab Clin Med. 1964 Dec;64:960–969. [PubMed] [Google Scholar]
  11. Pennington J. E., Reynolds H. Y. Pharmacokinetics of gentamicin sulfate in bronchial secretions. J Infect Dis. 1975 Feb;131(2):158–162. doi: 10.1093/infdis/131.2.158. [DOI] [PubMed] [Google Scholar]
  12. Rattie E. S., Ravin L. J. Pharmacokinetic interpretation of blood levels and urinary excretion data for cefazolin and cephalothin after intravenous and intramuscular administration in humans. Antimicrob Agents Chemother. 1975 May;7(5):606–613. doi: 10.1128/aac.7.5.606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ratzan K. R., Ruiz C., Irvin G. L., 3rd Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease. Antimicrob Agents Chemother. 1974 Oct;6(4):426–431. doi: 10.1128/aac.6.4.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Reller L. B., Karney W. W., Beaty H. N., Holmes K. K., Turck M. Evaluation of cefazolin, a new cephalosporin antibiotic. Antimicrob Agents Chemother. 1973 Apr;3(4):488–497. doi: 10.1128/aac.3.4.488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. SCHMIDT L. H., WALLEY A. The influence of the dosage regimen on the therapeutic effectiveness of penicillin G in experimental lobar pneumonia. J Pharmacol Exp Ther. 1951 Dec;103(4):479–488. [PubMed] [Google Scholar]
  16. Simon C., Malerczyk V., Brahmstaedt E., Toeller W. Cefazolin, ein neues Breitspektrum-Antibiotikum. Dtsch Med Wochenschr. 1973 Dec 21;98(51):2448–2450. doi: 10.1055/s-0028-1107275. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES